CorMedix combines elite-quality fundamentals and a 3-of-4 earnings beat streak with a technically confirmed downtrend and short-squeeze setup, making it a quality-value name awaiting a momentum inflection.
Thesis pillars
- Elite Quality Compounder Metrics→Stable
- Earnings Beat Streak Value→Stable
- Death Cross Momentum Risk→Stable
- +2 more pillars — see the Why tab for full reasoning
CorMedix Inc. (CRMD) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $8.35. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $8.61. Engine's entry $8.35 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~84% (cyclical peak); Elevated risk factors.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence... Read more
Wait for pullback to $8.35. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $8.61. Engine's entry $8.35 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~84% (cyclical peak); Elevated risk factors. Chart setup: RSI 47 mid-range, Bollinger mid-band. Quality-value play. Wait for momentum improvement. Score 7.2/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — CorMedix Inc.
Latest news
- NEWS Is CRMD Stock a Buy Now After Strong Growth and New Risks? - TradingView — TradingView positive
- NEWS Is CRMD Stock a Buy Now After Strong Growth and New Risks? - Yahoo Finance — Yahoo Finance positive
- NEWS CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path - Yahoo Finance — Yahoo Finance positive
- NEWS CorMedix Inc.(NasdaqGM: CRMD) added to Russell 3000E Value Benchmark - marketscreener.com — marketscreener.com positive
- NEWS CorMedix Inc.(NasdaqGM: CRMD) added to Russell 3000 Value Benchmark - marketscreener.com — marketscreener.com positive
Generated 2026-07-05T19:50:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·3 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $8.35. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $8.61. Engine's entry $8.35 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Earnings expected to decline ~84% (cyclical peak); Elevated risk factors. Chart setup: RSI 47 mid-range, Bollinger mid-band. Quality-value play. Wait for momentum improvement. Target $13.22 (+53.5%), stop $7.77 (−10.8%), A.R:R 3.6:1. Score 7.2/10, moderate confidence.
Take-profit target: $13.22 (+58.3% upside). Target $13.22 (+53.5%), stop $7.77 (−10.8%), A.R:R 3.6:1. Stop-loss: $7.77.
Earnings expected to decline ~84% (cyclical peak); Elevated risk factors; Below 200-MA, MA slope -7.0%/30d (confirmed downtrend).
CorMedix Inc. trades at a P/E of 4.0 (forward 25.0). TrendMatrix value score: 8.6/10. Verdict: Buy (Wait for Entry).
12 analysts cover CRMD with a consensus score of 4.2/5. Average price target: $15.
What does CorMedix Inc. do?CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for...
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.